Drug intelligence / Profile preview

AB0017

Development stage: Unknown
Lead developer: Protheragen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

AB0017 is a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), currently in Phase I development for the treatment of hemophilia. Developed by Protheragen, the drug functions by inhibiting TFPI, a natural anticoagulant that regulates the early stages of the blood coagulation cascade. By blocking the inhibitory effect of TFPI on Factor Xa and the Factor VIIa-Tissue Factor complex, AB0017 enhances thrombin generation and promotes clot formation. This mechanism is designed to provide a bypass therapy for patients with hemophilia A or B, including those who have developed inhibitors against replacement factors.

Targets

TFPI (Tissue factor pathway inhibitor)

Beyond the preview

Go deeper on AB0017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB0017.

Explore the full profile